

## Onureg - (200 mg and 300 mg ; Tablets)

|                              |                                                                                                                                                                                                                                                                                                           |                             |                     |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| <b>Generic Name</b>          | Azacitidine                                                                                                                                                                                                                                                                                               | <b>Innovator</b>            | Celgene             |
| <b>Dosage</b>                | 200 mg and 300 mg ; Tablets                                                                                                                                                                                                                                                                               | <b>Branded US Sales</b>     | Less Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                                                                                                                                               | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                                                                                               | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None                                                                                                                                                                                                                                                                                                      | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRI) following intensive induction chemotherapy and are not able to complete intensive curative therapy. |                             |                     |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                                                       |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.